SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 54.84+0.2%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: kenhott who wrote (14020)11/10/2004 11:12:19 PM
From: Archie Meeties  Read Replies (3) of 52153
 
A good example of teaching an old drug new tricks. Niacin's benefits were known the 70's, and in fact, as I read the pr, I don't see anything that looks like new information. The marketing angle is "all parts of the lipid profile are important", and there's clearly merit to the argument.

I am a little curious about the flushing. This is the same side effect that made the non-extended release form sometimes intolerable (but even then, a side effect that diminished over time and could be minimized through plate tectonic speed titration). If it's present in the majority of patients, then I wonder if part of the trick is prescribing niaspan only at night - perhaps it's soporific as well and nobody notices the flushing? If I'm remember right a metabolite of niacin is thought to be an endogenous benzodiazepine receptor ligand.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News